ACHNYSEWholesale-Medical, Dental & Hospital Equipment & SuppliesFiscal year ends December 31
ACCENDRA HEALTH INC/VA/
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$0.22−0.01 (-6.30%)
Close on Oct 19, 2026
- Market cap
- $16.89M
- P/E (TTM)
- –
- Dividend yield
- –
ACCENDRA HEALTH INC/VA/ revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Solutions | – | – | – | – | – | – | – | – | $8.79B | $9.19B | – | – |
| Global Products | – | – | – | – | – | – | – | – | $391.63M | $343.67M | – | – |
| Proprietary Products | – | – | – | – | – | – | – | – | $504.03M | $539.58M | – | – |
| Global Products | – | – | – | – | $2.66B | $1.81B | $1.43B | $1.11B | $504.03M | $539.58M | – | – |
| Global Solutions | – | – | – | – | $7.86B | $7.21B | $8.24B | $8.77B | $9.19B | $9.54B | – | – |
| Patient Direct | – | $2.68B | $2.55B | $2.06B | $959.67M | $817.75M | – | – | – | – | – | – |
| Products & Healthcare Services | – | $8.02B | $7.78B | $7.90B | $8.83B | $7.66B | – | – | – | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Solutions | – | – | – | – | – | – | – | – | $134.06M | $165.50M | – |
| Global Products | – | – | – | – | – | – | – | – | -$3.86M | $5.60M | – |
| Proprietary Products | – | – | – | – | – | – | – | – | $32.95M | $53.80M | – |
| Global Products | – | – | – | – | $371.93M | $259.93M | $65.05M | $75.69M | $38.46M | $59.38M | – |
| Global Solutions | – | – | – | – | $66.63M | $30.95M | $83.59M | $108.76M | $141.09M | $175.51M | – |
| Patient Direct | – | $260.16M | $246.86M | $193.75M | $57.97M | $67.66M | – | – | – | – | – |
| Products & Healthcare Services | – | $53.01M | $57.81M | $175.31M | $384.39M | $215.70M | – | – | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diabetes | $783.37M | $777.48M | $723.32M | – | – | – | – | – | – | – | 28.4% | +0.8% |
| Sleep therapy | $740.05M | $702.95M | $669.78M | – | – | – | – | – | – | – | 26.8% | +5.3% |
| Home respiratory therapy | $433.05M | $435.95M | $457.68M | – | – | – | – | – | – | – | 15.7% | -0.7% |
| Other | $288.19M | $268.27M | $254.97M | – | – | – | – | – | – | – | 10.4% | +7.4% |
| Ostomy | $212.84M | $195.92M | $177.89M | – | – | – | – | – | – | – | 7.7% | +8.6% |
| Wound care | $188.51M | $192.41M | $170.95M | – | – | – | – | – | – | – | 6.8% | -2.0% |
| Urology | $116.02M | $107.12M | $97.99M | – | – | – | – | – | – | – | 4.2% | +8.3% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | $10.46B | $10.06B | $9.53B | $9.25B | $8.13B | $8.87B | $9.26B | $8.90B | $9.34B | – | – |
| France | – | – | – | – | – | – | – | – | $39.28M | $38.76M | – | – |
| Germany | – | – | – | – | – | – | – | – | $49.23M | $47.51M | – | – |
| United Kingdom | – | – | – | – | – | – | – | – | $175.70M | $169.87M | – | – |
| Other European countries | – | – | – | – | – | – | – | – | $97.92M | $87.53M | – | – |
| Ireland | – | – | – | – | – | – | – | – | $56.94M | $41.21M | – | – |
| International | – | $242.94M | $275.29M | $429.44M | $534.98M | $349.77M | $339.34M | $157.04M | $419.07M | $384.89M | – | – |
From the segment and revenue-disaggregation notes of Accendra Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.